Last reviewed · How we verify
Pegylated IFN- alpha 2b
Pegylated IFN- alpha 2b is a Interferon-alpha Small molecule drug developed by Ain Shams University. It is currently FDA-approved for Chronic hepatitis C, Chronic hepatitis B, Melanoma. Also known as: PEG-IFN alpha-2b, PEG-Intron™.
Pegylated interferon-alpha 2b activates innate immune responses by binding to interferon-alpha receptors, enhancing antiviral and antiproliferative activity.
Pegylated interferon-alpha 2b activates innate immune responses by binding to interferon-alpha receptors on immune cells, enhancing antiviral and anti-tumor activity. Used for Chronic hepatitis C, Chronic hepatitis B, Melanoma.
At a glance
| Generic name | Pegylated IFN- alpha 2b |
|---|---|
| Also known as | PEG-IFN alpha-2b, PEG-Intron™ |
| Sponsor | Ain Shams University |
| Drug class | Interferon-alpha |
| Target | Interferon-alpha receptor (IFNAR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Virology, Oncology |
| Phase | FDA-approved |
Mechanism of action
Interferon-alpha 2b is a cytokine that binds to type I interferon receptors on cell surfaces, triggering JAK-STAT signaling pathways that upregulate antiviral genes and promote apoptosis in infected or malignant cells. Pegylation extends the drug's half-life by conjugating polyethylene glycol, allowing for less frequent dosing while maintaining therapeutic efficacy. This formulation is used primarily in chronic viral infections and certain malignancies.
Approved indications
- Chronic hepatitis C
- Chronic hepatitis B
- Melanoma
- Follicular lymphoma
Common side effects
- Flu-like symptoms (fever, chills, fatigue)
- Headache
- Myalgia
- Depression
- Thrombocytopenia
- Neutropenia
- Thyroid dysfunction
Key clinical trials
- Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV (PHASE2)
- Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma (PHASE3)
- ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission (PHASE3)
- Inactive HBsAg Carriers (IHCs) Treated With Pegylated Interferon α2b Based Intervention Therapy (NA)
- Re-treatment of HCV Following DAA Failure (NA)
- A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms (PHASE3)
- Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2) (PHASE1)
- Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pegylated IFN- alpha 2b CI brief — competitive landscape report
- Pegylated IFN- alpha 2b updates RSS · CI watch RSS
- Ain Shams University portfolio CI
Frequently asked questions about Pegylated IFN- alpha 2b
What is Pegylated IFN- alpha 2b?
How does Pegylated IFN- alpha 2b work?
What is Pegylated IFN- alpha 2b used for?
Who makes Pegylated IFN- alpha 2b?
Is Pegylated IFN- alpha 2b also known as anything else?
What drug class is Pegylated IFN- alpha 2b in?
What development phase is Pegylated IFN- alpha 2b in?
What are the side effects of Pegylated IFN- alpha 2b?
What does Pegylated IFN- alpha 2b target?
Related
- Drug class: All Interferon-alpha drugs
- Target: All drugs targeting Interferon-alpha receptor (IFNAR)
- Manufacturer: Ain Shams University — full pipeline
- Therapeutic area: All drugs in Immunology, Virology, Oncology
- Indication: Drugs for Chronic hepatitis C
- Indication: Drugs for Chronic hepatitis B
- Indication: Drugs for Melanoma
- Also known as: PEG-IFN alpha-2b, PEG-Intron™
- Compare: Pegylated IFN- alpha 2b vs similar drugs
- Pricing: Pegylated IFN- alpha 2b cost, discount & access